6
IMMULITE 2000 Homocysteine (PIL2KHO-14, 2007-11-20)
factor for vascular disease. New Eng J Med
1991;324:1149-55. 5) Deloughery TG, Evans A,
Sadeghi A,et al. Common mutation in
methylenetetrahydrofolate reductase:
Correlation with homocysteine metabolism and
late-onset vascular disease. Circulation
1996;94:3074-78. 6) Bostom AG, Selhub J.
Homocysteine and arteriosclerosis: Subclinical
and clinical disease associations. Circulation
1999;99:2361-63. 7) Boushey CJ, Beresford
SAA, et al. A quantitative assessment of plasma
homocysteine as a risk factor for vascular
disease. JAMA 1995;274(13):1049-57. 8)
Guttormsen AB, Svarstad E, et al. Elimination of
homocysteine in subjects with end-stage renal
failure. Irish J Med Sci 1995;164:8. 9) Bostom
AG, Lathrop, L. Hyper-homocysteinemia in end-
stage renal disease (ESDR): Prevalence,
etiology and potential relationship to arterio-
sclerotic outcomes. Kidney Int 1997;52:10-20.
10) Refsum H, Ueland PM. Clinical significance
of pharmacological modulation of homocysteine
metabolism. TIPS 1990;11:411-16. 11) Ueland
PM, Refsum H, Stabler SP, et al. Total
homocysteine in plasma or serum: Methods and
clinical applications. Clin Chem 1993;39:1764-
79. 12) Nehler MR, Taylor LM, Porter JM.
Homocysteine as a risk factor for
atherosclerosis: A Review. Cardiovasc Pathol
1997;6:1-9.
Technical Assistance
In the United States, contact Siemens
Medical Solutions Diagnostics Technical
Services department.
Tel: 800.372.1782 or 973.927.2828
Fax: 973.927.4101. Outside the United
States, contact your National Distributor.
The Quality System of Siemens Medical
Solutions Diagnostics is certified to
ISO 13485:2003.
Tables and Graphs
Precision (µmol/L)
Within-Run
1
Total
2
Mean
3
SD
4
CV
5
SD CV
1 3.94 0.29 7.4% 0.41 10.4%
2 9.88 0.47 4.8% 0.75 7.6%
3 11.1 0.38 3.4% 0.46 4.1%
4 25.9 1.06 4.1% 1.31 5.1%
Specificity (µmol/L)
Compound
1
Amount
Added
2
µmol/L
% Cross
reactivity
3
Adenosine 5000
ND
S-adenosyl-L-methionine
500
0.6%
Cystathionine 500
6.1%
L-Cysteine 100000
ND
Glutathione 100000
ND
ND: Not detectable.
4
Linearity (µmol/L)
Dilution
1
Observed
2
Expected
3
%O/E
4
1 8
in
8
5
19.2
—
—
4
in
8 9.47
9.60
99%
2
in
8 4.94
4.80
103%
1
in
8 2.11
2.40
88%
2 8
in
8 25.2
—
—
4
in
8 13.8
12.6
110%
2
in
8 6.15
6.30
98%
1
in
8 3.34
3.15
106%
3 8
in
8 31.6
—
—
4
in
8 15.7
15.8
99%
2
in
8 7.44
7.90
94%
1
in
8 3.37
3.95
85%
4 8
in
8 47.5
—
—
4
in
8 24.2
23.7
102%
2
in
8 11.5
11.9
97%
1
in
8 4.91
5.94
83%
Recovery (µmol/L)
Solution
1
Observed
2
Expected
3
%O/E
4
1 — 7.41
—
—
A 13.3 13.3 100%
B 20.2 19.5 104%
C 34.4 32.0 108%
2 — 9.96
—
—
A 14.7 15.7 94%
B 22.6 22.0 103%
C 36.2 34.5 105%
3 — 13.3
—
—
A 16.9 18.9 89%
B 26.0 25.1 104%
C 32.0 37.6 85%
